A new report shows that US corporations and their umbrella organizations are allocating increasing amounts of money for shaping delegates’ interventions at WHO, with potentially disastrous effects on health

Obstruction by pharmaceutical companies from the Global North and misuse of monopoly privileges continue to slow down research into new vaccines and medicines, with disastrous effects for people’s health in the Global South. Discussions at the 75th World Health Assembly did little to address this

This year’s World Health Assembly prominently featured discussions obesity. However, the implementation of serious policies to deal with the issue is being undermined by the multi-stakeholder approach, which is letting industries influence the conversation. 

Sustainable financing of the WHO was one of the most anticipated topics of the 75th World Health Assembly. Although progress has been made through efforts of a designated working group, worries remain that the planned increase will not be enough to meet actual needs

Without stronger action to counter the influence of transnational alcohol and food companies, industry-propelled health harm will continue to persist

Baba Aye from Public Services International (PSI) looks back at the major discussion points and highlights of the 75th World Health Assembly

Lauren Paremoer from the People’s Health Movement South Africa talks about how the recent World Health Assembly and the Ministerial Conference of the WTO will have a major role in deciding the course of the response in case of new health emergencies and pandemics.

The World Health Assembly is going to discuss topics of great relevance for our times, but in order to make necessary change the WHO must step up and recognize the fundamental issues plaguing global governance of health

The World Health Assembly Special Session in November will be considering the benefits of developing a new international instrument on pandemic preparedness and response. Rich countries are using the opportunity to sideline discussions on equity in public health

A century after the discovery of insulin, quality-assured access remains hindered by high prices. The WHO resolution for transparency in pricing of insulin aims at dealing with Big Pharma market monopoly

One year into the pandemic, the World Health Assembly is holding its annual meeting. The continued financial challenges loomed over delegates as they discussed the possibility of a Pandemic Treaty, local production of medicines, and WHO’s COVID-19 response

During the 74th session of World Health Assembly, several countries emphasized the need to end unilateral coercive measures which end up serving as a collective punishment by restricting access to basic necessities